Independent investment analyst, Managing Director EQUI.TS GmbH_ Big data analytics is poised to change the way business is done in the life sciences. A string of recent M&A transactions illustrate this trend.

Danish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications.

Using only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk.

Norwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor.

Bioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US.

After €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for centronuclear myopathy into clinical development.

Two listed Scandinavian biotech companies are about to merge into one. Medical Prognosis Institute A/S (Nasdaq First North Stockholm) in Denmark and Oncology Venture Sweden AB (Aktie Torget) in Sweden aim to create what they call a one-stop-shop for personalised cancer treatments. 

Microbiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases.

The Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Deborah Dunsire will take up her new position on 1 September 2018.

Dialysis product and service provider Fresenius Medical Care has placed €500m notes. Yesterday, the medtech giant had to come to terms with a sharp drop in share price.